You are here


  • Novel tumour endothelial marker: antibody target for anti-angiogenesis approaches.
  • Expression is highly restricted to tumour endothelial cells.
  • Evidence of role in endothelial migration and tube formation.
  • CLEC14A KO mice and inhouse generated murine monoclonal antibodies demonstrate in vivo tumor burden reduction and inhibition of invasion.
  • Potential role as cancer biomarker.
  • Intellectual property protected with two patent applications
The Opportunity: 

Tumor endothelial markers (TEMs) that are highly expressed in human tumor vasculature compared with vasculature in normal tissue hold clear therapeutic potential. C-type lectin CLEC14A is a novel TEM, a transmembrane protein that is specifically expressed on the surface of tumour endothelial cells.


Prof. Roy Bicknell, Cancer Research UK Molecular Angiogenesis Group, University of Birmingham.


1. Mura M et al; Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 2011 Jun 27
2. Rho SS et al; Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion. Biochem Biophys Res Commun. 2011 Jan 7
3. Noy PJ et al; Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene. 2015 Mar 9

Development Stage: 
Downloadable PDF: